
Longevity Startup Reports Positive Alzheimer's Trial Data, $1.8B Valuation
247 Health News Editorial
·23 May 2026
·3 min read
·healthtechRetro Biosciences reports positive early trial data for Alzheimer's treatment targeting protein clearance, achieving $1.8B valuation. The cellular rejuvenation approach shows no dose-limiting toxicities with full results expected in August.
Originally reported by STAT News
References
- 1.DeAngelis, A. (2024). Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion. STAT News. https://www.statnews.com/2026/05/22/retro-biosciences-longevity-valuation/
- 2.Sweeney, P., Park, H., Baumann, M., Dunlop, J., Frydman, J., Kopito, R., McCampbell, A., Leblanc, G., Venkateswaran, A., Nurmi, A., & Hodgson, R. (2017). Protein misfolding in neurodegenerative diseases: implications and strategies. Translational Neurodegeneration, 6(1), 6. https://doi.org/10.1186/s40035-017-0077-5
- 3.Mullard, A. (2021). Controversial Alzheimer's drug approval could affect other diseases. Nature Reviews Drug Discovery, 20(9), 649-650. https://doi.org/10.1038/d41573-021-00120-0
- 4.López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023). Hallmarks of aging: An expanding universe. Cell, 186(2), 243-278. https://doi.org/10.1016/j.cell.2022.11.001
- 5.Salloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F., Tian, Y., Umans, K., Wang, G., Singhal, P., Budd Haeberlein, S., & Wetzel-Smith, M. (2022). Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurology, 79(1), 13-21. https://doi.org/10.1001/jamaneurol.2021.4161
- 6.Ocampo, A., Reddy, P., Martinez-Redondo, P., Platero-Luengo, A., Hatanaka, F., Hishida, T., Li, M., Lam, D., Kurita, M., Beyret, E., Araoka, T., Vazquez-Ferrer, E., Donoso, D., Roman, J. L., Xu, J., Rodriguez Esteban, C., Nuñez, G., Nuñez Delicado, E., Campistol, J. M., Guillen, I., Guillen, P., & Izpisua Belmonte, J. C. (2016). In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell, 167(7), 1719-1733. https://doi.org/10.1016/j.cell.2016.11.052
- 7.Medin, T., Lourenco, J., Khodadadi-Jamayran, A., Ye, K., & Tsirigos, A. (2023). Investment trends in longevity biotechnology. Nature Biotechnology, 41(4), 442-445. https://doi.org/10.1038/s41587-023-01689-4
- 8.Kennedy, B. K., Berger, S. L., Brunet, A., Campisi, J., Cuervo, A. M., Epel, E. S., Franceschi, C., Lithgow, G. J., Morimoto, R. I., Pessin, J. E., Rando, T. A., Richardson, A., Schadt, E. E., Wyss-Coray, T., & Sierra, F. (2014). Geroscience: linking aging to chronic disease. Cell, 159(4), 709-713. https://doi.org/10.1016/j.cell.2014.07.039
2
247 Health News Editorial
247 Health News is a medical intelligence platform delivering evidence-based research appraisals, clinical trial monitoring, and health technology news for healthcare professionals.
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service

